This clinical trial is focused on studying asthma, a condition that affects the airways in the lungs, making it difficult to breathe. The study is testing a new treatment called lunsekimig, also known by its code name SAR443765. This treatment is given as a solution for injection under the skin. The trial will compare the effects of lunsekimig with a placebo to see how well it works in reducing asthma flare-ups in adults who have high-risk asthma and are not currently eligible for other biologic treatments.

The purpose of the study is to evaluate how effective lunsekimig is in preventing asthma exacerbations, which are episodes where asthma symptoms become much worse. Participants in the study will receive either the lunsekimig injection or a placebo and will be monitored over a period of time to see how their asthma symptoms change. The study will also look at other factors, such as lung function, asthma control, and quality of life, to get a comprehensive understanding of the treatment’s impact.

Throughout the study, researchers will collect information on any side effects experienced by participants, as well as how the body responds to the treatment. This will help determine the safety and tolerability of lunsekimig. The study aims to provide valuable insights into whether this new treatment can offer a beneficial option for people with high-risk asthma who have limited treatment choices.